Aaron Len Magno

Aaron Len Magno

Auto-generated profile, based on publicly available information

Aaron Len Magno

Research Centre, Royal Perth Hospital, Perth, WA 6000, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
LHLakshini Yasaswi Herat
Lakshini Yasaswi Herat
AMAaron L. Magno
Aaron L. Magno
CRCaroline Rudnicka
Caroline Rudnicka
JHJana Hricova
Jana Hricova
RCRevathy Carnagarin
Revathy Carnagarin
VMVance B. Matthews
Vance B. Matthews
Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression. Inhibition of SGLT2 prevented weight gain, reduced blood pressure, significantly reduced elevations of tyrosine hydroxylase and norepinephrine, and protects against endothelial dysfunction. These findings provide evidence for significant crosstalk between activation of the sympathetic nervous system and SGLT2 regulation and possible ancillary effects on endothelial function, which may contribute to the observed cardiorenal protective effects of SGLT2 inhibition.

1 February 2011 in Endocrine Reviews
Verified
Journal Article
Closed access
AMAaron L. Magno
Aaron L. Magno
BWBryan K. Ward
Bryan K. Ward
TRThomas Ratajczak
Thomas Ratajczak
Compelling evidence of a cell surface receptor sensitive to extracellular calcium was observed as early as the 1980s and was finally realized in 1993 when the calcium-sensing receptor (CaR) was cloned from bovine parathyroid tissue. Initial studies relating to the CaR focused on its key role in extracellular calcium homeostasis, but as the amount of information about the receptor grew it became evident that it was involved in many biological processes unrelated to calcium homeostasis. The CaR responds to a diverse array of stimuli extending well beyond that merely of calcium, and these stimuli can lead to the initiation of a wide variety of intracellular signaling pathways that in turn are able to regulate a diverse range of biological processes. It has been through the examination of the molecular characteristics of the CaR that we now have an understanding of how this single receptor is able to convert extracellular messages into specific cellular responses. Recent CaR-related reviews have focused on specific aspects of the receptor, generally in the context of the CaR's role in physiology and pathophysiology. This review will provide a comprehensive exploration of the different aspects of the receptor, including its structure, stimuli, signalling, interacting protein partners, and tissue expression patterns, and will relate their impact on the functionality of the CaR from a molecular perspective.

1 December 2015 in The Lancet
Verified
Journal Article
Closed access
ERElizabeth P Rakoczy
Elizabeth P Rakoczy
CLChooi-May Lai
Chooi-May Lai
AMAaron L Magno
Aaron L Magno
MWMatthew E Wikstrom
Matthew E Wikstrom
MFMartyn French
Martyn French
ICIan J Constable
Ian J Constable

1 December 2016 in EBioMedicine
Verified
Journal Article
Open access
ICIan J. Constable
Ian J. Constable
CPCora M. Pierce
Cora M. Pierce
CLChooi-May Lai
Chooi-May Lai
AMAaron L. Magno
Aaron L. Magno
MDMariapia A. Degli-Esposti
Mariapia A. Degli-Esposti
ERElizabeth P. Rakoczy
Elizabeth P. Rakoczy
We present the results of a Phase 2a randomized controlled trial investigating the safety, and secondary endpoints of subretinal rAAV.sFLT-1 gene therapy in patients with active wet age-related macular degeneration (wAMD). All patients (n=32), (ClinicalTrials.gov; NCT01494805), received ranibizumab injections at baseline and week 4, and thereafter according to prespecified criteria. Patients in the gene therapy group (n=21) received rAAV.sFLT-1 (1×1011vg). All patients were assessed every 4weeks to the week 52 primary endpoint. Ocular adverse events (AEs) in the rAAV.sFLT-1 group were mainly procedure related and self-resolved. All 11 phakic patients in the rAAV.sFLT-1 group showed progression of cataract following vitrectomy. No systemic safety signals were observed and none of the serious AEs were associated with rAAV.sFLT-1. AAV2 capsid was not detected and rAAV.sFLT-1 DNA was detected transiently in the tears of 13 patients. ELISPOT analysis did not identify any notable changes in T-cell response. In the rAAV.sFLT-1 group 12 patients had neutralizing antibodies (nAb) to AAV2. There was no change in sFLT-1 levels in bodily fluids. In the rAAV.sFLT-1 group, Best Corrected Visual Acuity (BCVA) improved by a median of 1.0 (IQR: -3.0 to 9.0) Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline compared to a median of -5.0 (IQR: -17.5 to 1.0) ETDRS letters change in the control group. Twelve (57%) patients in the rAAV.sFLT-1 group maintained or improved vision compared to 4 (36%) in the control group. The median number of ranibizumab retreatments was 2.0 (IQR: 1.0 to 6.0) for the gene therapy group compared to 4.0 (IQR: 3.5 to 4.0) for the control group. Interpretation rAAV.sFLT-1 combined with the option for co-treatment appears to be a safe and promising approach to the treatment of wAMD. National Health and Medical Research Council of Australia (AP1010405), Lions Eye Institute, Perth Australia, Avalanche Biotechnologies, Menlo Pk, CA, USA.

1 August 2012 in Clinical Biochemistry
Verified
Journal Article
Closed access
BWBryan K. Ward
Bryan K. Ward
AMAaron L. Magno
Aaron L. Magno
JWJohn Peter Walsh
John Peter Walsh
TRThomas Ratajczak
Thomas Ratajczak

1 May 2014 in Experimental Eye Research
Verified
Journal Article
Closed access
JWJoanna Wisniewska-Kruk
Joanna Wisniewska-Kruk
IKIngeborg Klaassen
Ingeborg Klaassen
IVIlse M.C. Vogels
Ilse M.C. Vogels
AMAaron L. Magno
Aaron L. Magno
CLChooi-May Lai
Chooi-May Lai
ERElizabeth P. Rakoczy
Elizabeth P. Rakoczy